Inclusion Criteria

-Disease Characteristics-

Histopathologic diagnosis of one of the following malignancies: ovarian carcinoma, all
non-mucinous epithelial histologies, including primary peritoneal and fallopian tube
carcinoma; malignant mesothelioma, except sarcomatous histology; squamous cell cancer of
the lung; squamous cell cancer of the cervix; or squamous cell cancer of the head and
neck.

Tissue block must be available for analysis. Tumor, initial or recurrent, must be
positive (at least 30% of tumor cells) for mesothelin by immunohistochemistry.

Recurrent unresectable disease after appropriate definitive therapy.

At least 4 weeks elapsed since any prior therapy, with recovery from side effects. No
concurrent anti-tumor treatment of any kind.

Measurable or evaluable tumor documented within 4 weeks prior to study entry.

-Patient Characteristics-

At least 18 years of age.

At least 12-week life expectancy.

Performance Status (ECOG) 0-2.

Adequate organ function, including: Absolute neutrophil count at least 1,500/mm3;
Platelets at least 75,000/mm3; Creatinine, Calcium, and total Bilirubin less than or equal
to the upper limit of normal; Liver enzymes AST and ALT less than or equal 2.5 x the upper
limit of normal; Albumin at least 3.0 g/dL; Oxygen (O2) saturation more than 93% (room
air).

Informed Consent signed in accordance with institutional criteria.

No known central nervous system (CNS) or spinal cord involvement by tumor.

No detectable antibody to SS1(dsFv)-PE38.

No concurrent antitumor therapy.

No cardiovascular condition NY Heart Association Grade II-IV, or any
clinically-significant pericardial effusion.

No infection requiring parenteral antibiotics; no HIV infection; and no seropositivity for
Hepatitis B and Hepatitis C.

Must not be pregnant or nursing. Females of child-bearing potential must use an effective
method of contraception.